Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERFORM: Fecal Microbiota Transplantation in Renal Cell Carcinoma
NCT04163289Phase 1Active, not recruiting
- Start
- Jan 2020
- Primary completion
- Nov 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Fecal Microbiota Transplantation Capsule in renal cell carcinoma (RCC). Primary endpoint: Occurrence of immune-related colitis associated with ipilimumab/nivolumab treatment at 28 months. Started Jan 2020; status: active, not recruiting.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04163289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04163289.